Phase 2 Sleep Disorders Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 65 years old
- People who have been diagnosed with opioid use disorder (a problematic pattern of opioid use) according to standard medical criteria, with signs of physical dependence on opioids
- People whose urine test shows the presence of fentanyl or a similar substance
- People who are interested in being treated with buprenorphine for opioid use disorder
- People who plan to stay in their current area for the full length of the study
- People who are able to reach and maintain a daily dose of at least 8mg of a buprenorphine/naloxone tablet placed under the tongue
- People who are willing to follow all study rules and procedures
- People who do not have serious ongoing medical or surgical conditions that the study doctors consider would prevent safe participation
Who may not be able to join:
- People for whom buprenorphine, long-acting injectable buprenorphine (Sublocade), or the sleep medication suvorexant is medically unsuitable according to their prescribing information
- People who are pregnant or breastfeeding
- People with a severe alcohol or benzodiazepine use disorder, or signs of physical dependence on alcohol or benzodiazepines
- People with a known allergy to any of the study medications
- People who have been prescribed suvorexant for sleep problems in the past 30 days
- People who are currently taking benzodiazepines or any other prescribed medication for sleep problems
- People whose urine test is positive for benzodiazepines at the screening visit or when entering the residential treatment program
- People who currently have narcolepsy, restless leg syndrome, or sleep paralysis
- People considered at high risk for sleep apnea
- People who have had suicidal behaviours in the past 30 days
- People with severely reduced liver or kidney function, based on specific blood test results (confirm with trial site for exact values)
- People who have had a clinically significant mental health condition in the past year that the study doctors judge would interfere with participation
- People who do not have access to stable housing, as an electronic pill dispenser that requires charging is part of the study
- People whose personal circumstances, such as an upcoming period of incarceration, would prevent them from completing the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Andrew S Huhn, Ph.D., Johns Hopkins University
Phone: 410-550-1971
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Total Sleep Time; Buprenorphine compliance as assessed by the number of study days complying with buprenorphine treatment
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.